-
Something wrong with this record ?
Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy
P. Pokorná, D. Michaličková, D. Tibboel, J. Berner
Status not-indexed Language English Country Switzerland
Document type Journal Article
Grant support
ISR Pfizer Grant 69506665
Pfizer
Institutional Program of Charles University in Prague (UNCE/MED/007)
Charles University
Charles University project Cooperatio - Pediatric sciences
Charles University
Charles University project Cooperatio - Pharmaceutical sciences
Charles University
NLK
Directory of Open Access Journals
from 2012
PubMed Central
from 2012
Europe PubMed Central
from 2012
ProQuest Central
from 2012-01-01
Open Access Digital Library
from 2012-01-01
Open Access Digital Library
from 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2012
- Publication type
- Journal Article MeSH
This study aimed to characterize the impact of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics (PK) of meropenem in neonates and children and to provide recommendations for meropenem dosing in this specific population of patients. Therapeutic drug monitoring (152 meropenem plasma concentrations) data from 45 patients (38 received ECMO) with a body weight (BW) of 7.88 (3.62-11.97) kg (median (interquartile range)) and postnatal age of 3 (0-465) days were collected. The population PK analysis was performed using NONMEM V7.3.0. Monte Carlo simulations were performed to assess the probability of target achievement (PTA) for 40% of time the free drug remained above the minimum inhibitory concentration (fT > MIC) and 100% fT > MIC. BW was found to be a significant covariate for the volume of distribution (Vd) and clearance (CL). Additionally, continuous renal replacement therapy (CRRT) was associated with a two-fold increase in Vd. In the final model, the CL and Vd for a typical patient with a median BW of 7.88 kg that was off CRRT were 1.09 L/h (RSE = 8%) and 3.98 L (14%), respectively. ECMO did not affect meropenem PK, while superimposed CRRT significantly increased Vd. We concluded that current dosing regimens provide acceptably high PTA for MIC ≤ 4 mg/L for 40% fT > MIC, but individual dose adjustments are needed for 100% fT > MIC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24012859
- 003
- CZ-PrNML
- 005
- 20240726151430.0
- 007
- ta
- 008
- 240723s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/antibiotics13050419 $2 doi
- 035 __
- $a (PubMed)38786147
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Pokorná, Pavla $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $u Department of Physiology and Pharmacology, Karolinska Institute and Karolinska University Hospital, 171 77 Stockholm, Sweden $u Department of Pediatric Surgery, Erasmus Medical Center Sophia Children's Hospital, 3062 PA Rotterdam, The Netherlands
- 245 10
- $a Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy / $c P. Pokorná, D. Michaličková, D. Tibboel, J. Berner
- 520 9_
- $a This study aimed to characterize the impact of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics (PK) of meropenem in neonates and children and to provide recommendations for meropenem dosing in this specific population of patients. Therapeutic drug monitoring (152 meropenem plasma concentrations) data from 45 patients (38 received ECMO) with a body weight (BW) of 7.88 (3.62-11.97) kg (median (interquartile range)) and postnatal age of 3 (0-465) days were collected. The population PK analysis was performed using NONMEM V7.3.0. Monte Carlo simulations were performed to assess the probability of target achievement (PTA) for 40% of time the free drug remained above the minimum inhibitory concentration (fT > MIC) and 100% fT > MIC. BW was found to be a significant covariate for the volume of distribution (Vd) and clearance (CL). Additionally, continuous renal replacement therapy (CRRT) was associated with a two-fold increase in Vd. In the final model, the CL and Vd for a typical patient with a median BW of 7.88 kg that was off CRRT were 1.09 L/h (RSE = 8%) and 3.98 L (14%), respectively. ECMO did not affect meropenem PK, while superimposed CRRT significantly increased Vd. We concluded that current dosing regimens provide acceptably high PTA for MIC ≤ 4 mg/L for 40% fT > MIC, but individual dose adjustments are needed for 100% fT > MIC.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Michaličková, Danica $u Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000296909846
- 700 1_
- $a Tibboel, Dick $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $u Department of Pediatric Surgery, Erasmus Medical Center Sophia Children's Hospital, 3062 PA Rotterdam, The Netherlands
- 700 1_
- $a Berner, Jonas $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic $u Department of Physiology and Pharmacology, Karolinska Institute and Karolinska University Hospital, 171 77 Stockholm, Sweden $u Pediatric Perioperative Medicine and Intensive Care, Astrid Lindgren Children's Hospital, Karolinska University Hospital, 171 76 Stockholm, Sweden $1 https://orcid.org/0000000212354776
- 773 0_
- $w MED00195446 $t Antibiotics (Basel) $x 2079-6382 $g Roč. 13, č. 5 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38786147 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151423 $b ABA008
- 999 __
- $a ok $b bmc $g 2125498 $s 1224722
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 13 $c 5 $e 20240503 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics (Basel) $x MED00195446
- GRA __
- $a ISR Pfizer Grant 69506665 $p Pfizer
- GRA __
- $a Institutional Program of Charles University in Prague (UNCE/MED/007) $p Charles University
- GRA __
- $a Charles University project Cooperatio - Pediatric sciences $p Charles University
- GRA __
- $a Charles University project Cooperatio - Pharmaceutical sciences $p Charles University
- LZP __
- $a Pubmed-20240723